Autoimmune Retinopathy

  • Sang Jin KimEmail author
Part of the Retina Atlas book series (RA)


Autoimmune retinopathy (AIR) is a group of presumed immune-mediated disorders characterized by antiretinal antibodies, retinal neuronal dysfunction, and visual impairment. It is thought that AIR is caused by cross-reactivity of serum autoantibodies directed against retinal and retinal-like antigens, leading to retinal degeneration (Comlekoglu et al. 2013; Grange et al. 2014; Forooghian et al. 2015; Grewal et al. 2014).


  1. Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev. 2009;8(5):410–4. Scholar
  2. Berson EL, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol. 1988;106(3):307–11.CrossRefGoogle Scholar
  3. Comlekoglu DU, Thompson IA, Sen HN. Autoimmune retinopathy. Curr Opin Ophthalmol. 2013;24(6):598–605. Scholar
  4. Davoudi S, Ebrahimiadib N, Yasa C, Sevgi DD, Roohipoor R, Papavasilieou E, Comander J, Sobrin L. Outcomes in autoimmune retinopathy patients treated with rituximab. Am J Ophthalmol. 2017;180:124–32. Scholar
  5. Duvoisin RM, Haley TL, Ren G, Strycharska-Orczyk I, Bonaparte JP, Morgans CW. Autoantibodies in melanoma-associated retinopathy recognize an epitope conserved between TRPM1 and TRPM3. Invest Ophthalmol Vis Sci. 2017;58(5):2732–8. Scholar
  6. Eo DR, Yun JH, Kim SJ. A case of nonparaneoplastic autoimmune retinopathy. J Korean Ophthalmol Soc. 2015;56(7):1134–40.CrossRefGoogle Scholar
  7. Ferreyra HA, Jayasundera T, Khan NW, He S, Lu Y, Heckenlively JR. Management of autoimmune retinopathies with immunosuppression. Arch Ophthalmol. 2009;127(4):390–7. Scholar
  8. Forooghian F, Cao S, Cui J, Matsubara JA. The enigma of autoimmune retinopathy. Int Ophthalmol Clin. 2015;55(2):81–91. Scholar
  9. Fox AR, Gordon LK, Heckenlively JR, Davis JL, Goldstein DA, Lowder CY, Nussenblatt RB, Butler NJ, Dalal M, Jayasundera T, Smith WM, Lee RW, Adamus G, Chan CC, Hooks JJ, Morgans CW, Detrick B, Sen HN. Consensus on the diagnosis and management of nonparaneoplastic autoimmune retinopathy using a modified Delphi approach. Am J Ophthalmol. 2016;168:183–90. Scholar
  10. Grange L, Dalal M, Nussenblatt RB, Sen HN. Autoimmune retinopathy. Am J Ophthalmol. 2014;157(2):266–272 e261. Scholar
  11. Grewal DS, Fishman GA, Jampol LM. Autoimmune retinopathy and antiretinal antibodies: a review. Retina. 2014;34(5):827–45. Scholar
  12. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol. 2001;21(3):173–87.CrossRefGoogle Scholar
  13. Ladewig G, Reinhold U, Thirkill CE, Kerber A, Tilgen W, Pfohler C. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. Br J Dermatol. 2005;152(5):931–8. Scholar
  14. Mizener JB, Kimura AE, Adamus G, Thirkill CE, Goeken JA, Kardon RH. Autoimmune retinopathy in the absence of cancer. Am J Ophthalmol. 1997;123(5):607–18.CrossRefGoogle Scholar
  15. Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol. 1976;81(5):606–13.CrossRefGoogle Scholar
  16. Thirkill CE, Tait RC, Tyler NK, Roth AM, Keltner JL. The cancer-associated retinopathy antigen is a recoverin-like protein. Invest Ophthalmol Vis Sci. 1992;33(10):2768–72.PubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Department of Ophthalmology, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea

Personalised recommendations